CategorySurgical robots
Overview
Plymouth, Minnesota-based medical device company developing the Edison Histotripsy System — a robotically assisted platform using focused ultrasound to non-invasively destroy liver tumors. FDA De Novo clearance October 2023. Raised $102M Series D led by Alpha Wave Ventures, valued at $3.75B. Expanding to kidney, pancreas, prostate applications.
Verified record
- Verified deployments
- None on file
- Active incidents
- None on file
Valuation of record
Company-claimedPriced roundSeries D post-money
Key facts
CEO
Form factor
FDA status
CE Mark
Founded
Stage
Product
FDA pathway
Data & sources
Web sources
4
4 sources backing this record.View all →
Models (1)
View all models →Current leadership (1)
- Steve Augustine CEOreported, not verified
Safety record
No incidents on record for HistoSonics.
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Full safety record: incidents, sourcing, and exposure data →
Recent coverage
HistoSonics in third-party press
Funding rounds (1)
- Series D2026-06-22
$102M · $3.8B post
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Record createdJul 23, 2026
Added to the verified registry
Sources (4)
Common questions
- What is HistoSonics?
- Plymouth, Minnesota-based medical device company developing the Edison Histotripsy System — a robotically assisted platform using focused ultrasound to non-invasively destroy liver tumors. FDA De Novo clearance October 2023. Raised $102M Series D led by Alpha Wave Ventures, valued at $3.75B. Expanding to kidney, pancreas, prostate applications.
- What does HistoSonics make?
- HistoSonics has 1 robot model on the DEPLOY registry: Edison Histotripsy System (HistoSonics builds physical robots).
- Who is the CEO of HistoSonics?
- Steve Augustine is the ceo of HistoSonics, per the DEPLOY registry.
- Where is HistoSonics headquartered?
- HistoSonics is headquartered in Plymouth, MN, USA.
- Where does HistoSonics operate robots?
- HistoSonics is a robot manufacturer and does not directly operate deployments on the DEPLOY registry. Its products are deployed by customer operators; see the company page for the verified deployment record.
- Is HistoSonics a top robotics company?
- On DEPLOY's intelligence score, which blends verified deployments, funding, hiring, media, safety, and IP signals, HistoSonics ranks in roughly the top 3% of companies tracked by the registry.
- When was HistoSonics founded?
- HistoSonics was founded in 2009.
- Is HistoSonics safe?
- HistoSonics has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.
Methodology: Verified · 4 sources (no primary) · last reviewed 2026-07-23
Verification posture
Verified
Low confidence
Review state
Stable
Last reviewed 2026-07-23
Sources by quality tier
- 4
- unclassified
- Unclassified source
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for HistoSonics.In the press
Recent coverage mentioning HistoSonics from third-party publications. Automatically surfaced; not part of the verified registry record.
HistoSonics Secures $102M Series D Financing
$102M Series D led by Alpha Wave Ventures. FDA De Novo cleared Edison system for liver tumor histotripsy. $3.75B valuation.
New Financing Values HistoSonics at $3.75B
HistoSonics valued at $3.75B in latest financing with participation from Yosemite and other strategic investors.
Machine-readable surfaces
- Markdown mirror: /companies/histosonics.md
- RSS feed: /companies/histosonics/feed.xml
- JSON-LD: embedded in this page’s head
- REST API: /v1/companies/fffa2127-5d46-4965-b510-cf96161154f0
- Revision history: /companies/histosonics/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Video
Histotripsy uses very high amplitude and short pulses (microseconds) of focused ultrasound to induce and control acoustic cavitation in the form of a histotrips
Mike Blue, President, CEO of HistoSonics, Inc. For more, visit: www.cednc.org/lsc
Learn more at www.gshealth.org
https://www.gshealth.org/robotic-surgery
The Latest News in technology you definitely don't want to MISS this 🤯 In this video you’ll discover, Fi's AI-powered dog collar that lets you monitor your pe
In this episode of The Innovation Frontier, we step into the operating room to tell the story of HistoSonics, a company trying to change how tumors are treated
Reality vs attention
HistoSonics draws attention at the 78th percentile but verifies reality at the insufficient-data level among surgical robots.
Analysis
Well-capitalized with $102M raised and recent funding activity. Limited public visibility and press coverage relative to peers.
Signal flags
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Jul 24, 2026